



EVITRADE CLOSES TERMS FOR ACQUIRING A MEDICAL MARKETPLACE APP

VANCOUVER, BC, Friday April 26, 2019 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) is pleased to announce that the Company has conditionally finalized terms for a binding agreement to acquire the software and portal for a medical marketplace app and have entered into a binding letter of intent for the same.

The company sees this asset as an opportunity to fulfill a key link as medical marketplace connector. It is a marketplace connection app which connects buyers with sellers. The app serves two functions: one, is a marketplace tool for finding local medical cannabis dispensaries and product overview. The second function is to provide a marketplace for new and used medical products. A planned future feature for both functions in the app will be capability the scheduling of secure pick-up and delivery of products to ensure user confidentiality and privacy.

The purchase price of the transaction is \$1,450,000 CAD and is to be completed based on milestones with the issuance of 7,037,037 common shares at a deemed price of \$0.135 per share and milestone cash payments. The acquisition is subject to the parties entering into a binding agreement. The mentioned letter of intent is subject to customary conditions in favour of the company.

EVITrade continues to fulfill its commitment to elevate the human condition through advanced medical solutions, research and effective health and wellness products.

Contact:

EVITRADE Health Systems Corp.
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com or ceo@auxellence.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets (OTCQB): <http://www.otcm Markets.com/stock/EVAHF/news>

About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)

EVITRADE Health Systems Corp. (formerly, Auxellence Health Corporation), is a technology company specializing in the Health and Life Sciences sector looking to deliver effective personalized health solutions with a higher degree of predictability and consistency.

The Company is focused on the following areas to help improve health: personalized medical care (including CBD usage monitoring and effects on the cardiovascular system), molecular biology, nutraceutical solutions and genetic tailoring.

Through its subsidiaries' focus on technologies involved in extracting and purifying CBD extracts for its personalized healthcare system, the Company may be the first to offer a complete quality assured vertically integrated "CBD Health System" for monitoring and recording the effects of CBD on your cardiovascular system.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements, including the risk that the contemplated binding agreement for the acquisition might not be entered into, might not be entered into on the terms mentioned in this news release, or that after entry into such agreement the acquisition might not close as anticipated. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.